135 related articles for article (PubMed ID: 32371619)
1. Metabolic Evolution of Brain Metastasis After Stereotactic Radiosurgery: Mismatch Between F-DOPA and FDG PET.
Cicone F; Carideo L; Villani V; Scaringi C; Bozzao A; Scopinaro F; Minniti G
Clin Nucl Med; 2020 Jul; 45(7):557-558. PubMed ID: 32371619
[TBL] [Abstract][Full Text] [Related]
2. Accuracy of F-DOPA PET and perfusion-MRI for differentiating radionecrotic from progressive brain metastases after radiosurgery.
Cicone F; Minniti G; Romano A; Papa A; Scaringi C; Tavanti F; Bozzao A; Maurizi Enrici R; Scopinaro F
Eur J Nucl Med Mol Imaging; 2015 Jan; 42(1):103-11. PubMed ID: 25182751
[TBL] [Abstract][Full Text] [Related]
3. Long-term metabolic evolution of brain metastases with suspected radiation necrosis following stereotactic radiosurgery: longitudinal assessment by F-DOPA PET.
Cicone F; Carideo L; Scaringi C; Romano A; Mamede M; Papa A; Tofani A; Cascini GL; Bozzao A; Scopinaro F; Minniti G
Neuro Oncol; 2021 Jun; 23(6):1024-1034. PubMed ID: 33095884
[TBL] [Abstract][Full Text] [Related]
4. [Differential diagnosis of local tumor recurrence or radionecrosis after stereotactic radiosurgery for treatment of brain metastasis].
Patsouris A; Augereau P; Tanguy JY; Morel O; Menei P; Rousseau A; Paumier A
Cancer Radiother; 2014 Mar; 18(2):142-6. PubMed ID: 24433952
[TBL] [Abstract][Full Text] [Related]
5. Brain metastases after stereotactic radiosurgery using the Leksell gamma knife: can FDG PET help to differentiate radionecrosis from tumour progression?
Belohlávek O; Simonová G; Kantorová I; Novotný J; Liscák R
Eur J Nucl Med Mol Imaging; 2003 Jan; 30(1):96-100. PubMed ID: 12483415
[TBL] [Abstract][Full Text] [Related]
6. 18F-FDOPA PET imaging of brain tumors: comparison study with 18F-FDG PET and evaluation of diagnostic accuracy.
Chen W; Silverman DH; Delaloye S; Czernin J; Kamdar N; Pope W; Satyamurthy N; Schiepers C; Cloughesy T
J Nucl Med; 2006 Jun; 47(6):904-11. PubMed ID: 16741298
[TBL] [Abstract][Full Text] [Related]
7. Radionecrosis versus disease progression in brain metastasis. Value of (18)F-DOPA PET/CT/MRI.
Hernández Pinzón J; Mena D; Aguilar M; Biafore F; Recondo G; Bastianello M
Rev Esp Med Nucl Imagen Mol; 2016; 35(5):332-5. PubMed ID: 27117985
[TBL] [Abstract][Full Text] [Related]
8. Differentiation of benign vs. malignant mass in a postirradiation cerebral arteriovenous malformation by 2-deoxy-2-[18F] fluoro-D-glucose positron emission tomography.
Raman A; Rothrock JF; Liu HG; Mountz JM
Mol Imaging Biol; 2004; 6(1):1-6. PubMed ID: 15018822
[TBL] [Abstract][Full Text] [Related]
9. Diagnostic impact of PET with 18F-FDG, 18F-DOPA and 3-O-methyl-6-[18F]fluoro-DOPA in recurrent or metastatic medullary thyroid carcinoma.
Beuthien-Baumann B; Strumpf A; Zessin J; Bredow J; Kotzerke J
Eur J Nucl Med Mol Imaging; 2007 Oct; 34(10):1604-9. PubMed ID: 17435996
[TBL] [Abstract][Full Text] [Related]
10. FDG PET/MRI Coregistration Helps Predict Response to Gamma Knife Radiosurgery in Patients With Brain Metastases.
Leiva-Salinas C; Muttikkal TJE; Flors L; Puig J; Wintermark M; Patrie JT; Rehm PK; Sheehan JP; Schiff D
AJR Am J Roentgenol; 2019 Feb; 212(2):425-430. PubMed ID: 30422717
[TBL] [Abstract][Full Text] [Related]
11. Current status of 18F-DOPA PET imaging in the detection of brain tumor recurrence.
Calabria F; Cascini GL
Hell J Nucl Med; 2015; 18(2):152-6. PubMed ID: 26187216
[TBL] [Abstract][Full Text] [Related]
12. New PET radiopharmaceuticals beyond FDG for brain tumor imaging.
Gulyás B; Halldin C
Q J Nucl Med Mol Imaging; 2012 Apr; 56(2):173-90. PubMed ID: 22617239
[TBL] [Abstract][Full Text] [Related]
13. The sensitivity and specificity of FDG PET in distinguishing recurrent brain tumor from radionecrosis in patients treated with stereotactic radiosurgery.
Chao ST; Suh JH; Raja S; Lee SY; Barnett G
Int J Cancer; 2001 Jun; 96(3):191-7. PubMed ID: 11410888
[TBL] [Abstract][Full Text] [Related]
14. Differentiation of local tumor recurrence from radiation-induced changes after stereotactic radiosurgery for treatment of brain metastasis: case report and review of the literature.
Kickingereder P; Dorn F; Blau T; Schmidt M; Kocher M; Galldiks N; Ruge MI
Radiat Oncol; 2013 Mar; 8():52. PubMed ID: 23497597
[TBL] [Abstract][Full Text] [Related]
15. Comparison of MRI and PET as Potential Surrogate Endpoints for Treatment Response After Stereotactic Radiosurgery in Patients With Brain Metastasis.
Suh CH; Kim HS; Jung SC; Choi CG; Kim SJ
AJR Am J Roentgenol; 2018 Dec; 211(6):1332-1341. PubMed ID: 30240297
[TBL] [Abstract][Full Text] [Related]
16. Impact of 3,4-dihydroxy-6-18F-fluoro-L-phenylalanine PET/CT on managing patients with brain tumors: the referring physician's perspective.
Walter F; Cloughesy T; Walter MA; Lai A; Nghiemphu P; Wagle N; Fueger B; Satyamurthy N; Phelps ME; Czernin J
J Nucl Med; 2012 Mar; 53(3):393-8. PubMed ID: 22323780
[TBL] [Abstract][Full Text] [Related]
17. (18)F-fluoromethylcholine (FCho), (18)F-fluoroethyltyrosine (FET), and (18)F-fluorodeoxyglucose (FDG) for the discrimination between high-grade glioma and radiation necrosis in rats: a PET study.
Bolcaen J; Descamps B; Deblaere K; Boterberg T; De Vos Pharm F; Kalala JP; Van den Broecke C; Decrock E; Leybaert L; Vanhove C; Goethals I
Nucl Med Biol; 2015 Jan; 42(1):38-45. PubMed ID: 25218024
[TBL] [Abstract][Full Text] [Related]
18. Value of 18F-3,4-dihydroxyphenylalanine PET/MR image fusion in pediatric supratentorial infiltrative astrocytomas: a prospective pilot study.
Morana G; Piccardo A; Milanaccio C; Puntoni M; Nozza P; Cama A; Zefiro D; Cabria M; Rossi A; Garrè ML
J Nucl Med; 2014 May; 55(5):718-23. PubMed ID: 24652828
[TBL] [Abstract][Full Text] [Related]
19. Although Non-diagnostic Between Necrosis and Recurrence, FDG PET/CT Assists Management of Brain Tumours After Radiosurgery.
Torrens M; Malamitsi J; Karaiskos P; Valotassiou V; Laspas F; Andreou J; Stergiou C; Prassopoulos V
In Vivo; 2016; 30(4):513-20. PubMed ID: 27381617
[TBL] [Abstract][Full Text] [Related]
20. Prospective trial evaluating the sensitivity and specificity of 3,4-dihydroxy-6-[18F]-fluoro-L-phenylalanine (18F-DOPA) PET and MRI in patients with recurrent gliomas.
Youland RS; Pafundi DH; Brinkmann DH; Lowe VJ; Morris JM; Kemp BJ; Hunt CH; Giannini C; Parney IF; Laack NN
J Neurooncol; 2018 May; 137(3):583-591. PubMed ID: 29330751
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
